Exelixis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

14.45B

Market cap14.45B

Price-Earnings ratio

18.33

Price-Earnings ratio18.33

Dividend yield

—

Dividend yield—

Average volume

2.32M

Average volume2.32M

High today

$59.50

High today$59.50

Low today

$57.90

Low today$57.90

Open price

$58.58

Open price$58.58

Volume

5.24M

Volume5.24M

52 Week high

$59.72

52 Week high$59.72

52 Week low

$33.76

52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $58.36. The company's market cap stands at 14.45B, with a P/E ratio of 18.33.

On 2026-09-20, Exelixis(EXEL) stock traded between a low of $57.90 and a high of $59.50. Shares are currently priced at $58.36, which is +0.8% above the low and -1.9% below the high.

The Exelixis(EXEL)'s current trading volume is 5.24M, compared to an average daily volume of 2.32M.

During the past year, Exelixis(EXEL) stock moved between $33.76 at its lowest and $59.72 at its peak.

EXEL News

TipRanks 2d

Exelixis Q3 2022 Earnings Report - Results, Call & Slides - TipRanks

...

Simply Wall St 3d

Can Exelixis Stay Cheap After A 185% Five Year Run?

has delivered a strong multi year share price run, and the question now is whether that move lines up with what the company earns today. With the stock recently...

Nasdaq 3d

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, select...

Analyst ratings

57%

of 21 ratings

Buy

33.3%

Hold

57.1%

Sell

9.5%

More EXEL News

Nasdaq 5d

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza...

Simply Wall St 5d

Exelixis Looks Fully Valued After FDA Review Delay

Exelixis (EXEL) is back in focus after the FDA extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer by three months, followin...

Nasdaq 6d

Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises

Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tu...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Sterling Infrastructure

Argan

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.